JP2021100934A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021100934A5 JP2021100934A5 JP2021029791A JP2021029791A JP2021100934A5 JP 2021100934 A5 JP2021100934 A5 JP 2021100934A5 JP 2021029791 A JP2021029791 A JP 2021029791A JP 2021029791 A JP2021029791 A JP 2021029791A JP 2021100934 A5 JP2021100934 A5 JP 2021100934A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- conr
- receptor
- apj
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 34
- 150000001875 compounds Chemical class 0.000 claims 29
- 125000006552 (C3-C8) cycloalkyl group Chemical class 0.000 claims 19
- 125000001072 heteroaryl group Chemical group 0.000 claims 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 16
- 208000035475 disorder Diseases 0.000 claims 16
- 102000005962 receptors Human genes 0.000 claims 16
- 108020003175 receptors Proteins 0.000 claims 16
- 125000003118 aryl group Chemical group 0.000 claims 13
- -1 adamantanyl Chemical group 0.000 claims 9
- 125000003342 alkenyl group Chemical group 0.000 claims 9
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims 8
- 208000031229 Cardiomyopathies Diseases 0.000 claims 8
- 208000032928 Dyslipidaemia Diseases 0.000 claims 8
- 206010020772 Hypertension Diseases 0.000 claims 8
- 206010061218 Inflammation Diseases 0.000 claims 8
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 8
- 208000008589 Obesity Diseases 0.000 claims 8
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims 8
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims 8
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 8
- 229940125364 angiotensin receptor blocker Drugs 0.000 claims 8
- 208000006673 asthma Diseases 0.000 claims 8
- 206010012601 diabetes mellitus Diseases 0.000 claims 8
- 230000004054 inflammatory process Effects 0.000 claims 8
- 208000019423 liver disease Diseases 0.000 claims 8
- 208000030159 metabolic disease Diseases 0.000 claims 8
- 230000004770 neurodegeneration Effects 0.000 claims 8
- 208000015122 neurodegenerative disease Diseases 0.000 claims 8
- 235000020824 obesity Nutrition 0.000 claims 8
- 230000008085 renal dysfunction Effects 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims 5
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 4
- 208000021908 Myocardial disease Diseases 0.000 claims 4
- 125000003282 alkyl amino group Chemical group 0.000 claims 4
- 125000005233 alkylalcohol group Chemical group 0.000 claims 4
- 239000002160 alpha blocker Substances 0.000 claims 4
- 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 claims 4
- 239000002876 beta blocker Substances 0.000 claims 4
- 229940097320 beta blocking agent Drugs 0.000 claims 4
- 239000000480 calcium channel blocker Substances 0.000 claims 4
- 239000002934 diuretic Substances 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 201000011461 pre-eclampsia Diseases 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000005012 alkyl thioether group Chemical group 0.000 claims 3
- 150000001356 alkyl thiols Chemical class 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 230000001882 diuretic effect Effects 0.000 claims 2
- 229940030606 diuretics Drugs 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- OUOJIFQQBPKAMU-UHFFFAOYSA-N tetrazol-5-one Chemical compound O=C1N=NN=N1 OUOJIFQQBPKAMU-UHFFFAOYSA-N 0.000 claims 1
- 150000003568 thioethers Chemical class 0.000 claims 1
- 150000003573 thiols Chemical class 0.000 claims 1
- 0 *C(*)(*)NC(c1n[n](*)c(I)c1)=O Chemical compound *C(*)(*)NC(c1n[n](*)c(I)c1)=O 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562265168P | 2015-12-09 | 2015-12-09 | |
| US201562265177P | 2015-12-09 | 2015-12-09 | |
| US62/265,177 | 2015-12-09 | ||
| US62/265,168 | 2015-12-09 | ||
| JP2018530026A JP2019501899A (ja) | 2015-12-09 | 2016-12-09 | 改良アペリンレセプター（ａｐｊ）アゴニストおよびその使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018530026A Division JP2019501899A (ja) | 2015-12-09 | 2016-12-09 | 改良アペリンレセプター（ａｐｊ）アゴニストおよびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021100934A JP2021100934A (ja) | 2021-07-08 |
| JP2021100934A5 true JP2021100934A5 (enExample) | 2021-08-19 |
| JP7195356B2 JP7195356B2 (ja) | 2022-12-23 |
Family
ID=57796972
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018530026A Pending JP2019501899A (ja) | 2015-12-09 | 2016-12-09 | 改良アペリンレセプター（ａｐｊ）アゴニストおよびその使用 |
| JP2021029791A Active JP7195356B2 (ja) | 2015-12-09 | 2021-02-26 | 改良アペリンレセプター（ａｐｊ）アゴニストおよびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018530026A Pending JP2019501899A (ja) | 2015-12-09 | 2016-12-09 | 改良アペリンレセプター（ａｐｊ）アゴニストおよびその使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US10100059B2 (enExample) |
| EP (1) | EP3386976A1 (enExample) |
| JP (2) | JP2019501899A (enExample) |
| KR (1) | KR20180090852A (enExample) |
| CN (1) | CN108602806B (enExample) |
| AU (1) | AU2016366310C1 (enExample) |
| BR (1) | BR112018011784A2 (enExample) |
| CO (1) | CO2018005871A2 (enExample) |
| HK (1) | HK1255452A1 (enExample) |
| IL (1) | IL259634A (enExample) |
| MA (1) | MA43417A (enExample) |
| MX (2) | MX391898B (enExample) |
| PE (1) | PE20190258A1 (enExample) |
| RU (2) | RU2766148C1 (enExample) |
| WO (1) | WO2017100558A1 (enExample) |
| ZA (1) | ZA201803301B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106459004B (zh) | 2014-06-06 | 2020-09-15 | 研究三角协会 | 爱帕琳肽受体(apj)激动剂及其用途 |
| CA2985542C (en) | 2015-05-20 | 2023-10-10 | Amgen Inc. | Triazole agonists of the apj receptor |
| RS59220B1 (sr) | 2015-06-03 | 2019-10-31 | Bristol Myers Squibb Co | 4-hidroksi-3-(heteroaril)piridin-2-on apj agonisti za primenu u lečenju kardiovaskularnih poremećaja |
| PE20190258A1 (es) | 2015-12-09 | 2019-02-25 | Res Triangle Inst | Antagonistas del receptor de la apelina (apj) mejorados y usos de los mismos |
| WO2017192485A1 (en) | 2016-05-03 | 2017-11-09 | Amgen Inc. | Heterocyclic triazole compounds as agonists of the apj receptor |
| EP3526209B1 (en) * | 2016-10-12 | 2025-04-16 | Research Triangle Institute | Heterocyclic apelin receptor (apj) agonists and uses thereof |
| US10689367B2 (en) | 2016-11-16 | 2020-06-23 | Amgen Inc. | Triazole pyridyl compounds as agonists of the APJ receptor |
| WO2018093579A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Triazole phenyl compounds as agonists of the apj receptor |
| WO2018097944A1 (en) | 2016-11-16 | 2018-05-31 | Amgen Inc. | Triazole furan compounds as agonists of the apj receptor |
| US11020395B2 (en) | 2016-11-16 | 2021-06-01 | Amgen Inc. | Cycloalkyl substituted triazole compounds as agonists of the APJ receptor |
| EP3541805B1 (en) | 2016-11-16 | 2020-10-14 | Amgen Inc. | Heteroaryl-substituted triazoles as apj receptor agonists |
| US11191762B2 (en) | 2016-11-16 | 2021-12-07 | Amgen Inc. | Alkyl substituted triazole compounds as agonists of the APJ Receptor |
| DK3692015T3 (da) | 2017-10-06 | 2022-11-21 | Univ Johns Hopkins | Hidtil ukendte glutaminantagonister og anvendelser deraf |
| WO2019071073A1 (en) | 2017-10-06 | 2019-04-11 | Forma Therapeutics, Inc. | INHIBITION OF THE SPECIFIC PEPTIDASE OF UBIQUITIN |
| MA50509A (fr) | 2017-11-03 | 2021-06-02 | Amgen Inc | Agonistes de triazole fusionnés du récepteur apj |
| MA52487A (fr) | 2018-05-01 | 2021-03-10 | Amgen Inc | Pyrimidinones substituées en tant qu'agonistes du récepteur apj |
| ES2988920T3 (es) | 2018-05-17 | 2024-11-22 | Forma Therapeutics Inc | Compuestos bicíclicos fusionados útiles como inhibidores de la peptidasa 30 específica de ubiquitina |
| AU2019356011B2 (en) | 2018-10-05 | 2025-02-06 | Forma Therapeutics, Inc. | Fused pyrrolines which act as Ubiquitin-Specific Protease 30 (USP30) inhibitors |
| JP2022545698A (ja) * | 2019-08-29 | 2022-10-28 | リサーチ トライアングル インスティテュート | アペリン受容体アゴニストのための方法および使用 |
| AU2022225215A1 (en) | 2021-02-25 | 2023-08-31 | Research Triangle Institute | Heteroaryl derivatives as apelin receptor agonists |
| CN120813365A (zh) * | 2023-01-03 | 2025-10-17 | 百爱及生物医药公司 | 爱帕琳肽受体激动剂和glp-1受体激动剂的组合疗法用于治疗与体重增加相关的疾病或病况 |
| WO2025213190A1 (en) * | 2024-04-05 | 2025-10-09 | BioAge Labs, Inc. | Methods of treating a disease or condition associated with weight gain |
| WO2025251084A1 (en) * | 2024-05-31 | 2025-12-04 | BioAge Labs, Inc. | Methods of treating a disease or condition associated with weight gain |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58194866A (ja) | 1982-05-07 | 1983-11-12 | Kureha Chem Ind Co Ltd | トリアゾ−ル誘導体及び該誘導体を含有する除草剤 |
| DE3316300A1 (de) | 1982-05-07 | 1983-11-24 | Kureha Kagaku Kogyo K.K., Tokyo | Heribizide zusammensetzung mit einem gehalt an einem derivat des 1,2,4-triazols als wirkstoff |
| JPS5998004A (ja) | 1982-11-25 | 1984-06-06 | Kureha Chem Ind Co Ltd | １，２，４―トリアゾール誘導体及び除草剤 |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5965695A (en) | 1990-05-15 | 1999-10-12 | Chiron Corporation | Modified peptide and peptide libraries with protease resistance, derivatives thereof and methods of producing and screening such |
| FR2665898B1 (fr) * | 1990-08-20 | 1994-03-11 | Sanofi | Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| FR2713225B1 (fr) * | 1993-12-02 | 1996-03-01 | Sanofi Sa | N-pipéridino-3-pyrazolecarboxamide substitué. |
| FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| FR2711140B1 (fr) | 1993-10-12 | 1996-01-05 | Sanofi Sa | 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant. |
| FR2732967B1 (fr) | 1995-04-11 | 1997-07-04 | Sanofi Sa | 1-phenylpyrazole-3-carboxamides substitues, actifs sur la neurotensine, leur preparation, les compositions pharmaceutiques en contenant |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| FR2741621B1 (fr) | 1995-11-23 | 1998-02-13 | Sanofi Sa | Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant |
| FR2757869B1 (fr) | 1996-12-31 | 1999-05-21 | Rhodia Chimie Sa | Utilisation de melanges a base de pt et de composes de metaux de transition autres que le pt pour ameliorer les proprietes de resistance a l'arc des elastomeres silicones |
| US7045532B2 (en) | 1999-04-30 | 2006-05-16 | Millennium Pharmaceuticals, Inc. | ACE-2 modulating compounds and methods of use thereof |
| GB9925962D0 (en) | 1999-11-02 | 1999-12-29 | Novartis Ag | Organic compounds |
| BR0209325A (pt) | 2001-05-03 | 2004-07-20 | Hoffmann La Roche | Forma de dosagem farmacêutica de mesilato de nelfinavir amorfo |
| CA2446904A1 (en) | 2001-05-24 | 2003-04-03 | Alexza Pharmaceuticals, Inc. | Delivery of drug esters through an inhalation route |
| US7109216B2 (en) | 2001-09-21 | 2006-09-19 | Solvay Pharmaceuticals B.V. | 1H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
| TWI231757B (en) | 2001-09-21 | 2005-05-01 | Solvay Pharm Bv | 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
| UY27450A1 (es) | 2001-09-24 | 2003-04-30 | Bayer Corp | Preparación y uso de derivados de imidazol para el tratamiento de la obesidad |
| AR038967A1 (es) | 2002-03-18 | 2005-02-02 | Solvay Pharm Bv | Derivados de 2,3 - diaril - pirazolidinas como inhibidores de enzimas que degradan la neurotensina |
| HRP20050053A2 (en) | 2002-09-19 | 2005-04-30 | Solvay Pharmaceuticals B.V. | 1 h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands |
| WO2005054204A2 (en) | 2003-11-26 | 2005-06-16 | Synchrony Biosciences, Inc. | Pharmaceutical compounds that regenerate in vivo |
| TW200526641A (en) * | 2003-12-26 | 2005-08-16 | Daiichi Seiyaku Co | Amidopyrazole derivatives |
| WO2005099705A2 (en) | 2004-03-24 | 2005-10-27 | Bayer Pharmaceuticals Corporation | Preparation of imidazole derivatives and methods of use |
| BRPI0516170A (pt) | 2004-09-29 | 2008-08-26 | Cordis Corp | formas de dosagens farmacêuticas estáveis e amorfas de compostos de rapamicina |
| AU2005296582A1 (en) | 2004-10-19 | 2006-04-27 | Daiichi Pharmaceutical Co., Ltd. | 1,5-diheterocycle-1H-triazole derivative |
| EP1928859A1 (en) | 2005-06-17 | 2008-06-11 | Carex SA | Pyrazole derivates as cannabinoid receptor modulators |
| ATE538650T1 (de) | 2006-03-10 | 2012-01-15 | Jenrin Discovery | Cannabinoid-rezeptor-antagonisten / inverse agonisten zur behandlung von übergewicht |
| CN106125048B (zh) | 2016-07-11 | 2019-05-24 | 浙江大华技术股份有限公司 | 一种声源定位方法及装置 |
| EP1903052A3 (en) | 2006-07-28 | 2008-04-02 | Faust Pharmaceuticals SA | APJ receptor ligands and uses thereof |
| EP2051966A2 (en) | 2006-08-09 | 2009-04-29 | Pfizer Products Inc. | Heterocycles useful as inhibitors of carbonic anhydrase |
| UY30892A1 (es) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| JP5464395B2 (ja) | 2008-02-01 | 2014-04-09 | 大陽日酸株式会社 | 重水素化された芳香環又は複素環を有する化合物の製造方法 |
| WO2009154754A2 (en) | 2008-06-17 | 2009-12-23 | Concert Pharmaceuticals, Inc. | Synthesis of deuterated morpholine derivatives |
| EP2334621A1 (en) | 2008-09-16 | 2011-06-22 | Concert Pharmaceuticals, Inc. | Deuterated 2-amino-3-hydroxypropanoic acid derivatives |
| CA2742528A1 (en) | 2008-11-04 | 2010-05-14 | Anchor Therapeutics, Inc. | Apj receptor compounds |
| BRPI0921097B8 (pt) * | 2008-11-21 | 2021-05-25 | Raqualia Pharma Inc | composto ou seu sal farmaceuticamente aceitável, intermediário do composto, composição farmacêutica e uso do composto |
| US20100160323A1 (en) | 2008-12-23 | 2010-06-24 | Alexander Bischoff | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE |
| CN101519430A (zh) | 2009-03-20 | 2009-09-02 | 中国农业大学 | 一类新型保幼激素合成抑制剂－苯丙-甘-亮三肽酰胺类似物 |
| US8835436B2 (en) | 2009-07-10 | 2014-09-16 | Green Cross Corporation | Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same |
| DE102009036604A1 (de) | 2009-07-30 | 2011-02-03 | Aicuris Gmbh & Co. Kg | Substituierte Bis-Arylpyrazolamide mit terminaler primärer Amidfunktionalisierung und ihre Verwendung |
| WO2011156557A2 (en) * | 2010-06-11 | 2011-12-15 | Thomas James B | Compounds active at the neurotensin receptor |
| WO2012160015A1 (en) | 2011-05-23 | 2012-11-29 | Sanofi | Process for the preparation of deuterated compounds containing n-alkyl groups |
| US8513244B2 (en) * | 2011-05-31 | 2013-08-20 | Theravance, Inc. | Neprilysin inhibitors |
| ES2560381T3 (es) | 2011-07-26 | 2016-02-18 | Sanofi | Derivados de ácido 3-heteroaroilamino-propiónico y su uso como productos farmacéuticos |
| US9815851B2 (en) | 2011-12-02 | 2017-11-14 | Phenex Pharmaceuticals Ag | Pyrrolo carboxamides as modulators of orphan nuclear receptor RAR-related orphan receptor-gamma (RORγ, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases |
| JP2013231000A (ja) | 2012-04-27 | 2013-11-14 | Dainippon Sumitomo Pharma Co Ltd | ３−アミノメチルピラゾール誘導体 |
| UY34832A (es) | 2012-05-31 | 2013-12-31 | Phenex Pharmaceuticals Ag | TIAZOLES SUSTITUIDOS POR CARBOXAMIDA O SULFONAMIDA Y DERIVADOS RELACIONADOS COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUÉRFANO RORy (lambda) |
| JO3215B1 (ar) | 2012-08-09 | 2018-03-08 | Phenex Pharmaceuticals Ag | حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy |
| EP2897615A4 (en) | 2012-09-18 | 2016-04-27 | Auspex Pharmaceuticals Inc | PHARMACOKINETIC FORMULATIONS OF DEUTERATED BENZOCHINOL INHIBITORS OF THE VESICLE MONOAMINE TRANSPORTER 2 |
| DK2897939T3 (en) | 2012-09-21 | 2017-05-08 | Sanofi Sa | BENZOIMIDAZOLCARBOXYL ACID AMIDE DERIVATIVES FOR THE TREATMENT OF METABOLIC OR CARDIOVASCULAR DISEASES |
| WO2014053533A1 (en) | 2012-10-05 | 2014-04-10 | Sanofi | Use of substituted 3-heteroaroylamino-propionic acid derivatives as pharmaceuticals for prevention/treatment of atrial fibrillation |
| US20150299166A1 (en) | 2012-12-20 | 2015-10-22 | Concert Pharmaceuticals, Inc. | Deuterated alk inhibitors |
| EP2970121B1 (en) | 2013-03-15 | 2017-12-13 | Araxes Pharma LLC | Covalent inhibitors of kras g12c |
| WO2014169278A1 (en) | 2013-04-12 | 2014-10-16 | Achillion Pharmaceuticals, Inc. | Highly active nucleoside derivative for the treatment of hcv |
| ES2705342T3 (es) | 2013-10-17 | 2019-03-22 | Vertex Pharma | Co-cristales de (S)-N-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propan-2-il)quinolin-4-carboxamida y derivados deuterados de la misma como inhibidores de DNA-PK |
| WO2015148465A1 (en) * | 2014-03-25 | 2015-10-01 | Research Triangle Institute | Pyrazole compounds selective for neurotensin 2 receptor |
| WO2015184011A2 (en) | 2014-05-28 | 2015-12-03 | Sanford-Burnham Medical Research Institute | Agonists of the apelin receptor and methods of use thereof |
| CN106459004B (zh) * | 2014-06-06 | 2020-09-15 | 研究三角协会 | 爱帕琳肽受体(apj)激动剂及其用途 |
| PE20190258A1 (es) | 2015-12-09 | 2019-02-25 | Res Triangle Inst | Antagonistas del receptor de la apelina (apj) mejorados y usos de los mismos |
| EP3526209B1 (en) | 2016-10-12 | 2025-04-16 | Research Triangle Institute | Heterocyclic apelin receptor (apj) agonists and uses thereof |
| JP2022545698A (ja) | 2019-08-29 | 2022-10-28 | リサーチ トライアングル インスティテュート | アペリン受容体アゴニストのための方法および使用 |
-
2016
- 2016-12-09 PE PE2018001082A patent/PE20190258A1/es unknown
- 2016-12-09 BR BR112018011784A patent/BR112018011784A2/pt not_active Application Discontinuation
- 2016-12-09 MX MX2018006979A patent/MX391898B/es unknown
- 2016-12-09 KR KR1020187018896A patent/KR20180090852A/ko not_active Ceased
- 2016-12-09 EP EP16826220.2A patent/EP3386976A1/en active Pending
- 2016-12-09 AU AU2016366310A patent/AU2016366310C1/en active Active
- 2016-12-09 JP JP2018530026A patent/JP2019501899A/ja active Pending
- 2016-12-09 RU RU2018118568A patent/RU2766148C1/ru active
- 2016-12-09 WO PCT/US2016/065808 patent/WO2017100558A1/en not_active Ceased
- 2016-12-09 MA MA043417A patent/MA43417A/fr unknown
- 2016-12-09 HK HK18114625.4A patent/HK1255452A1/zh unknown
- 2016-12-09 US US15/374,386 patent/US10100059B2/en not_active Ceased
- 2016-12-09 CN CN201680081397.9A patent/CN108602806B/zh not_active Expired - Fee Related
- 2016-12-09 RU RU2021133849A patent/RU2021133849A/ru unknown
-
2018
- 2018-05-17 ZA ZA2018/03301A patent/ZA201803301B/en unknown
- 2018-05-18 US US15/983,519 patent/US10954247B2/en active Active
- 2018-05-27 IL IL259634A patent/IL259634A/en unknown
- 2018-06-07 CO CONC2018/0005871A patent/CO2018005871A2/es unknown
- 2018-06-07 MX MX2022002026A patent/MX2022002026A/es unknown
-
2020
- 2020-05-04 US US16/974,363 patent/USRE49594E1/en active Active
- 2020-10-28 US US17/082,650 patent/US11535630B2/en active Active
-
2021
- 2021-02-26 JP JP2021029791A patent/JP7195356B2/ja active Active